#United States #Whippany #Apotex #Halo Pharmaceuticals #sterile filling

Apotex Strengthens U.S. Manufacturing with New Partnership

In a significant move, Apotex Corp. has announced a strategic partnership with Halo Pharmaceuticals to enhance its sterile filling capabilities in the United States. This collaboration involves a substantial investment that grants Apotex access to a considerable portion of the sterile injectable filling capacity being established at Halo’s facility in Whippany, New Jersey.

The partnership marks a vital step in Apotex's ongoing effort to bolster its domestic manufacturing operations, aligning with the company's comprehensive Journey of Health strategy aimed at strengthening the U.S. pharmaceutical infrastructure and research capabilities. With this alliance, Apotex aims to tap into immediate sterile filling capacity, presenting a viable alternative to the traditional greenfield development approach.

Halo Pharmaceuticals is recognized for its integrated development and manufacturing services across various dosage forms, particularly in sterile injectables. This collaboration allows Apotex to bring its robust sterile processing experience, regulatory compliance knowledge, and commercialization capabilities into play, while also gaining access to vital vial and pre-filled syringe production facilities.

Christine Baeder, President of Apotex U.S. and LATAM, expressed enthusiasm regarding the investment, stating, "This investment underscores our commitment to our 'Made in the U.S.' initiative and is consistent with our broader focus on our Journey of Health strategy. We see this partnership as a pathway to enhance flexibility within our sterile injectables network, facilitating efficient capacity usage while also reflecting our deep commitment to the sterile injectables market."

For its part, Halo Pharmaceuticals welcomed the addition of Apotex as a partner, with CEO Lee Karras stating, "We are thrilled to collaborate with Apotex as they implement their Made in the U.S. strategy for injectables. Our facility will still maintain extensive capacity for other clients seeking vial, syringe, and cartridge sterile filling CDMO services."

The arrangement highlights an existing collaborative relationship between Apotex and Halo, which previously included non-sterile manufacturing programs. As the Whippany facility prepares for regulatory inspections as part of its qualification process, Apotex is poised to provide support for technical and operational readiness. However, the results of regulatory inspections and any subsequent approvals will still hinge on the FDA’s evaluations.

In addition to advancing Apotex's operational capabilities, this partnership underscores a pivotal moment for U.S. pharmaceutical manufacturing, aiming to cater to the increasing demand for sterile injectable medications. The collaboration not only enhances Apotex's operational flexibility but also plays a critical role in ensuring the steady supply of high-quality injectable products to the market.

Overall, this partnership represents a strategic alignment between two organizations committed to improving health access through enhanced manufacturing capabilities. Apotex continues to hold a significant position in the global pharmaceutical landscape with its wide array of generic and innovative health products, aspiring towards providing affordable medications to millions of individuals across the world.

As Apotex integrates these new capabilities into its network, the pharmaceutical industry will be watching closely to see how this partnership transforms U.S. sterile injectable manufacturing and enhances market access across the Americas.